Tayo Addo, MD
Interventional Cardiology · Dallas, TXNPI 1457328403
Payments from drug & device makers
Across 70 payments — averaging $61.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Terumo Medical Corporation$1K
- Abbott$905
- Boston Scientific$399
- Bard Peripheral Vascular, Inc.$266
- Opsens Inc.$257
- GE HealthCare$234
- plus $790 from 8 others
What the payments were for
- Consulting fees$2506%
- Travel & lodging$57713%
- Food & beverage$3,24375%
- Education$2526%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Terumo Medical Corporation | 11 | $1,471 |
| Abbott | 32 | $905 |
| Boston Scientific | 5 | $399 |
| Bard Peripheral Vascular, Inc. | 4 | $266 |
| Opsens Inc. | 2 | $257 |
| GE HealthCare | 2 | $234 |
| Medtronic | 3 | $232 |
| Recor Medical Inc | 1 | $146 |
| Abiomed | 4 | $142 |
| AbbVie | 1 | $112 |
| Shockwave Medical, Inc | 2 | $78 |
| Corcym Inc | 1 | $31 |
| Lantheus Medical Imaging, Inc. | 1 | $25 |
| Teleflex LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Glidesheath$737
- Navicross$487
- GlideWire$487
- OptoWire$233
- OptoMonitor$233
- Resolute$153
- AVVIGO Guidance System$152
- PARADISE RENAL DENERVATION SYSTEM$146
- Xience Sierra Coronary Stent System$146
- GLIDESHEATH SLENDER$135
- TR Band$133
- Lutonix Drug Coated Balloon$115
- Humira$112
- GENERAL - STENTS$112
How this compares
$4,322 in reported general payments places this provider in the 20th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $33,508 |
| EntrestoSacubitril/Valsartan | 19 | $23,449 |
| JardianceEmpagliflozin | 16 | $22,541 |
| XareltoRivaroxaban | 25 | $19,715 |
| Metoprolol Succinate | 81 | $1,795 |
| Ezetimibe | 35 | $896 |
| Carvedilol | 93 | $852 |
| Atorvastatin Calcium | 130 | $809 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 86 | $775 |
| Losartan Potassium | 65 | $717 |
| Rosuvastatin Calcium | 40 | $635 |
| Amlodipine Besylate | 81 | $623 |
| ClopidogrelClopidogrel Bisulfate | 56 | $605 |
| Spironolactone | 35 | $493 |
| Lisinopril | 47 | $491 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Dallas
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Cara Ann EastDallas$3M
- Byung ParkDallas$735K
- Anthony BavryDallas$359K
- Donald WurzburgDallas$341K
- Tony DasDallas$263K
- Zachary RosolDallas$257K
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.